|Articles|June 1, 1999

June 1999
Volume 5
Issue 6

Continuation of Postmenopausal Hormone Replacement Therapy in a Large Health Maintenance Organization: Transdermal Matrix Patch versus Oral Estrogen Therapy

Author(s)Bruce Ettinger, MD, Alice Pressman, MS

Download PDF: Continuation of Postmenopausal Hormone Replacement Therapy in a Large Health Maintenance Organization: Transdermal Matrix Patch versus Oral Estrogen Therapy

Articles in this issue

about 27 years ago

Article

Variations in and Correlates of Length of Stay in Academic Hospitals among Patients with Heart Failure Resulting from Systolic Dysfunction

about 27 years ago

Article

Continuity of Care: Is It Cost Effective?

about 27 years ago

Article

Nursing Facilities and Managed Care

about 27 years ago

Article

The Role of Respiratory Care Practitioners in a Changing Healthcare System: Emerging Areas of Clinical Practice

about 27 years ago

Article

The Impact of TennCare on Patient Satisfaction with Care

about 27 years ago

Article

Topical Corticosteroids: Considerations for Appropriate Use

about 27 years ago

Article

Variation in Length of Stay in Patients Hospitalized with Congestive Heart Failure

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

Readability of Hospital Patient Financial Policy Documents

BySamantha Randall, BA,Sumedha Raghu, MS,Ella Cho,Nina Linh Nguyen, MHA,Erin Trish, PhD,Erin L. Duffy, PhD, MPH

July 7th 2026

Continuation of Postmenopausal Hormone Replacement Therapy in a Large Health Maintenance Organization: Transdermal Matrix Patch versus Oral Estrogen Therapy

Articles in this issue

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Readability of Hospital Patient Financial Policy Documents

Trending on AJMC

AI Chatbots Score Below 28% on Colorectal Cancer Questions

5 Notable FDA Approvals From the First Half of 2026

FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma

Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues

INCA033989 May Address Unmet Need in Mutant Calreticulin Myelofibrosis: Claire Harrison, MD

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Continuation of Postmenopausal Hormone Replacement Therapy in a Large Health Maintenance Organization: Transdermal Matrix Patch versus Oral Estrogen Therapy

Articles in this issue

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Readability of Hospital Patient Financial Policy Documents

Trending on AJMC

AI Chatbots Score Below 28% on Colorectal Cancer Questions

5 Notable FDA Approvals From the First Half of 2026

FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma

Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues

INCA033989 May Address Unmet Need in Mutant Calreticulin Myelofibrosis: Claire Harrison, MD